JOINN Laboratories (China) Co., Ltd. Class H (HK:6127)
:6127
Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$13.62 - HK$28.70
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.46M
Market Cap
HK$27.78B
Enterprise ValueHK$25.38B
Total Cash (Recent Filing)HK$2.49B
Total Debt (Recent Filing)HK$12.48M
Price to Earnings (P/E)50.5
Beta1.55
Next Earnings
Sep 01, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)0.66
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.80Price Target Upside-20.45% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.63
Revenue Forecast (FY)HK$2.21B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Very Low LeverageExtremely low leverage and an equity-heavy capital structure provide durable financial flexibility. This allows the company to fund operations, invest in lab capacity, and weather demand volatility without relying on external debt, supporting long-term contract delivery and strategic investments.
Positive Operating Cash GenerationConsistent positive operating cash flow underpins the business's ability to fund day-to-day operations and reinvest in capabilities. Over a multi-month horizon this supports servicing long-duration CRO engagements, maintaining lab infrastructure, and reducing dependence on external financing for growth.
Durable CRO Fee-for-service Business ModelA fee-for-service CRO model aligns revenue with contracted project delivery and benefits from the secular trend of outsourcing preclinical work. That structural demand from pharma/biotech clients supports predictable project-based revenues and long-term client relationships if quality and capacity are maintained.
Bears Say
Multi-year Top-line Contraction And Uneven Operating PerformanceA sustained multi-year revenue decline reduces visibility and undermines scale benefits. Even with a recent TTM rebound, uneven performance increases execution risk for winning new contracts and maintaining utilization, limiting durable margin expansion and making growth reliant on successful client wins.
Sharp Gross Margin CompressionMarked gross-margin deterioration suggests weaker pricing power or rising direct costs (supplies, models, labor). Persistently lower gross margins erode operating leverage and constrain the firm’s ability to invest in higher-value services, threatening long-term profitability and return on capital.
Volatile And Declining Free Cash FlowPronounced FCF volatility and a sharp TTM decline weaken the firm’s ability to consistently fund capex, dividends, or working capital needs. Over a 2–6 month horizon this raises the risk that cash swings could force heavier reliance on reserves or external funding for strategic spending.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$13.62 and its highest was HK$28.70 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$27.78B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 90 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.367 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.298.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Overvalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.033 which represents an annual dividend yield of 0.15%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.09.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.367 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went down -1.441%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.02%
12-Months-Change
Fundamentals
Return on Equity
5.98%
Trailing 12-Months
Asset Growth
12.65%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.
6127 Stock 12 Month Forecast
Average Price Target
HK$16.80
▼(-20.45% Downside)
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---